Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors of The Cancer Genome Atlas: exploration beyond single-agent therapy.
Christianne PersenaireBenjamin G BitlerBradley R CorrPublished in: medRxiv : the preprint server for health sciences (2024)
Epithelial ovarian cancer can be highly lethal, with limited therapeutic options for patients without BRCA mutations or non-homologous recombination deficient disease. Folate receptor alpha (FRα)-targeting agents have shown promise in the setting of platinum-sensitive and platinum-resistant ovarian cancer, both alone and in combination with available therapies, but the relationship of FRα to other treatment-driving biomarkers is unknown. This study identifies potential targetable mutations in FRα-expressing tumors, including PIK3CA and FGF/R family proteins, and provides a basis for future investigations of novel combinations of FRα-targeting agents with PIK3CA, mTOR, FGF/R, and VEGF inhibitors.
Keyphrases
- end stage renal disease
- ejection fraction
- dna damage
- newly diagnosed
- dna repair
- genome wide
- high grade
- cancer therapy
- prognostic factors
- peritoneal dialysis
- endothelial cells
- cell proliferation
- single cell
- gene expression
- squamous cell carcinoma
- risk assessment
- drug delivery
- protein kinase
- dna methylation
- young adults
- oxidative stress
- binding protein
- bone marrow
- patient reported outcomes
- combination therapy
- replacement therapy
- climate change
- lymph node metastasis